Bk-MBDB
From Wikipedia, the free encyclopedia
 |
|
|
Bk-MBDB
|
|
| Systematic (IUPAC) name | |
| 2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | C12H15NO3 |
| Mol. mass | 221.252 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
bk-MBDB, also known as "butylone", is a psychoactive drug first synthesized by Koeppe, Ludwig and Zeile which is mentioned in their 1967 paper. It remained an obscure product of academia until 2005 when it was synthesized by a chemical supply company. It has since been explored as a possible entheogen. The full name of the chemical is beta-keto-MBDB, and as the name suggests, it shares the same relationship to MBDB as methylone does to MDMA. The dosage range is not fully understood but seems to be lower than for MBDB. No formal research has been done on this chemical, and nothing is known of its pharmacological profile or toxicology, although anecdotal reports indicate it is subjectively similar to but milder than methylone.
When it first was available, the alternate names butylone and mebylone were proposed. These were abandoned because Butylone was found to be a trademarked name for pentobarbital, and mebylone because it was phonetically too easy to confuse with methylone and because it did not really reflect the chemical's structure.
[edit] External links
[edit] Categorization
|
|||||
